2 citations
,
August 2024 in “International Journal of Dermatology” This study found that treating patients with androgenetic alopecia using exosomes from adipose tissue stem cells over 24 weeks significantly increased hair density and patient satisfaction without severe adverse effects, suggesting a promising alternative treatment for hair loss.
5 citations
,
August 2024 in “Skin Research and Technology” This study found that KLB and EIF3C are important in the progression of vitiligo and AA, suggesting they could be biomarkers and early diagnostic targets.
August 2024 in “International Journal of Dermatology” This research commentary discusses the potential role of exosomes in treating hair loss, although no results are reported. The authors highlight prior studies indicating exosomes' promise for hair regeneration and explore their emerging application in dermatology.
20 citations
,
January 2024 in “Journal of the European Academy of Dermatology and Venereology” This study conducted a meta-analysis and found that among therapies for alopecia areata, baricitinib_4 mg was most likely to be effective, followed by ritlecitinib and ivarmacitinib, while other treatments like dupilumab and secukinumab were less effective.
4 citations
,
January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.
October 2023 in “The Cochrane library” This review identified that baricitinib increases both short- and long-term hair regrowth in patients with alopecia areata compared to placebo, but found inconclusive results for serious adverse effects, while evidence for other treatments remains very uncertain.
October 2023 in “Acta dermato-venereologica (Print)” This study found that patients with severe alopecia areata had significantly lower serum zinc levels compared to healthy controls, and a negative correlation between zinc levels and disease severity was observed, suggesting that zinc assessment and supplementation trials may be warranted in this population.
August 2023 in “Dermatology and Therapy” This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.
3 citations
,
July 2023 in “International journal of molecular sciences” This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.
8 citations
,
May 2023 in “Cureus” In this case report, a 64-year-old woman developed alopecia areata after starting the IL-17A inhibitor secukinumab for psoriasis, highlighting a potential rare side effect of this treatment, with only three similar cases reported in the literature.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.
91 citations
,
May 2023 in “Journal of Cutaneous Medicine and Surgery” Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
7 citations
,
April 2023 in “Frontiers in immunology” This source reports that a network meta-analysis found oral baricitinib and ruxolitinib to be effective and safe for treating alopecia areata, significantly improving response rates over placebos and showing fewer adverse effects than steroid treatments, though precise dosing needs further study.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
February 2023 in “Lasers in Medical Science” 
1 citations
,
January 2023 in “Przegląd Dermatologiczny” This review discusses current and emerging treatments for alopecia areata, emphasizing systemic treatments for moderate to severe cases, and reports no new clinical results.
4 citations
,
October 2022 in “Genes” This review discusses the role of cutaneous and intestinal microbiota in the development of alopecia areata, summarizing current literature without reporting new clinical results.
3 citations
,
September 2021 in “JAAD case reports” This review discusses the increased autoimmune events associated with the use of denosumab, a biologic agent for managing postmenopausal osteoporosis and skeletal complications from malignancy, but reports no new data.
14 citations
,
September 2021 in “Journal of Inflammation Research” This study suggests that female patients with alopecia areata, especially those with nail abnormalities and atopic diseases, may have higher rates of coexisting autoimmune diseases.
56 citations
,
January 2021 in “Clinical and Experimental Medicine” This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.
23 citations
,
October 2020 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.
22 citations
,
April 2020 in “Frontiers in Cellular and Infection Microbiology” This study found significant differences in scalp microbiome composition and volatile organic metabolites between individuals with alopecia areata and healthy controls, suggesting potential microbiome-related therapeutic interventions for hair growth disorders.
13 citations
,
April 2020 in “Dermatology and therapy” This systematic review assessed cyclosporine's effectiveness with or without corticosteroids for treating alopecia areata, finding combined therapy more effective and with a lower recurrence rate than monotherapy, especially for severe cases, though results varied by alopecia type.
2 citations
,
January 2020 in “Skin appendage disorders” This study in Mexican patients with alopecia areata found that body hair involvement was linked to disease progression, while treatment adherence was associated with both remission and progression.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.
12 citations
,
August 2019 in “Dermatitis” This case report describes a 42-year-old woman with atopic dermatitis, whose alopecia areata reactivated rapidly after starting dupilumab, possibly indicating an unrecognized adverse effect in AD patients.
45 citations
,
April 2019 in “International Immunology” This review discusses the mechanisms behind alopecia areata and primary cicatricial alopecia and reports no new clinical results, aiming to guide the development of targeted treatments.
73 citations
,
April 2019 in “Experimental Dermatology” This review explores the hair follicle microbiome's interaction with the immune system, discussing its potential clinical implications for scalp health and disease but reports no new clinical results.
29 citations
,
March 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.
20 citations
,
March 2019 in “Journal of The European Academy of Dermatology and Venereology” In this study, 5% minoxidil significantly improved outcomes for children and adults with patchy alopecia areata compared to placebo, with moderate quality evidence and no severe adverse events reported, though more research is needed to address remaining uncertainties.
32 citations
,
January 2019 in “American Journal of Clinical Dermatology” This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.
33 citations
,
January 2019 in “Acta Dermato Venereologica” This case report suggests potential effectiveness of dupilumab for alopecia areata, though hair regrowth may result from indirect effects on inflammation in atopic dermatitis.
11 citations
,
January 2019 in “Acta Dermato Venereologica” Omalizumab may cause hair loss.
49 citations
,
December 2018 in “JAAD case reports” This case report describes a patient who developed alopecia after 18 weeks of treatment with dupilumab for atopic dermatitis.
42 citations
,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
95 citations
,
November 2018 in “Australasian journal of dermatology” This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.
12 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” This review found insufficient evidence to determine methotrexate's effectiveness for maintaining regrowth in extensive alopecia areata, and suggests its potential role in inducing regrowth when combined with corticosteroids.
89 citations
,
March 2018 in “The Journal of Dermatology” This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.
45 citations
,
January 2018 in “International Journal of Dermatology” This review explores nail changes associated with alopecia areata, noting their prevalence and impact on appearance and function, but reports no new clinical findings; the authors call for larger controlled trials.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
19 citations
,
August 2017 in “American journal of clinical dermatology” This analysis reports that hepatitis B surface protein antigen exposure is associated with an increased risk of alopecia areata.
24 citations
,
January 2017 in “Pediatric dermatology” This study found that 1% anthralin ointment effectively promoted hair growth in children with chronic, severe alopecia areata, showing complete or partial responses in 70% of participants over 12 months, without serious adverse events.
16 citations
,
November 2016 in “Journal of Cosmetic and Laser Therapy” This review highlights that laser and light treatments could serve as safe and effective alternatives to current therapies for alopecia areata, with the excimer laser showing positive results, though further randomized controlled trials are necessary to establish optimal treatment protocols.
62 citations
,
October 2016 in “Dermatologic Therapy” This study found that platelet-rich plasma was more effective for treating alopecia areata than topical 5% minoxidil, leading to earlier hair regrowth and reduction in hair abnormalities.
68 citations
,
November 2015 in “The Journal of Allergy and Clinical Immunology” In this study, three patients with extensive alopecia areata showed varying degrees of hair regrowth after 20 weeks of treatment with ustekinumab, a cytokine-targeting therapy.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.
162 citations
,
October 2014 in “Autoimmunity reviews” This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.
19 citations
,
September 2014 in “JAMA Dermatology” Eosinophilic infiltrate is not a reliable indicator for diagnosing chronic alopecia areata.
72 citations
,
July 2014 in “American journal of clinical dermatology” This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.
105 citations
,
March 2014 in “British journal of dermatology/British journal of dermatology, Supplement” In this study, patients with alopecia areata were found to have significantly lower serum vitamin D levels compared to those with vitiligo and healthy individuals, with lower levels correlating with increased disease severity.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
53 citations
,
September 2011 Other common signs, not just the well-known immune cells around hair bulbs, are important for diagnosing hair loss from alopecia areata.
244 citations
,
January 2010 in “Journal of the American Academy of Dermatology” This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.
65 citations
,
January 2009 in “Annals of Dermatology” In this study, oral zinc supplementation for twelve weeks increased serum zinc levels in alopecia areata patients with low zinc, showing positive hair regrowth in 66.7% of participants, though this was not statistically significant.
64 citations
,
November 2008 in “Journal of The American Academy of Dermatology” This study observed that acute diffuse and total alopecia, a subtype of alopecia areata, typically resolves rapidly and spontaneously within about six months, even without treatment, suggesting a favorable prognosis.
45 citations
,
July 2008 in “International Journal of Dermatology” This study found that oral sulfasalazine led to varying hair regrowth outcomes in patients with persistent alopecia areata, with 56.3% showing moderate to good responses.
163 citations
,
November 2003 in “Journal of Investigative Dermatology” This study found that women with androgenetic alopecia or alopecia areata have significantly lower serum ferritin levels than those without hair loss, suggesting a potential link between these types of alopecia and decreased iron stores.
21 citations
,
December 1997 in “The Journal of Dermatology” In this case report, a 57-year-old Japanese woman with alopecia areata, associated with myasthenia gravis and thymoma, showed significant improvement after undergoing thymectomy and receiving high doses of glucocorticosteroids.
105 citations
,
December 1995 in “British journal of dermatology/British journal of dermatology, Supplement” This retrospective study concluded that PUVA treatment is generally ineffective for alopecia areata, with low effective success rates for partialis, totalis, and universalis types.
